Germantown, Maryland, and Hilden, Germany, November 5, 2018 – QIAGEN announced the worldwide launch of the new DNeasy Plant Pro Kit today, a system for extraction of high-quality DNA from varied plant samples with a range of features that give it a clear best in class position, such as further improved yield and effective inhibitor removal. The new kit includes the innovative Bead-Beating technology for significantly higher sample disruption efficiency. DNeasy Plant Pro Kit significantly outperforms all broadly available alternatives when it comes to increased yield and efficient inhibitor removal, showing no inhibition of a sensitive IC PCR.
Plant samples often contain high levels of secondary metabolites like polysaccharides, lipids, terpenes or polyphenols which are difficult to remove. Additionally, plant samples come in high diversity from young leaves to seeds of very hard matter, which requires a thorough sample disruption for optimal release of DNA. QIAGEN’s solutions include QIAGEN’s unique „Bead-Beating“ technology and also apply patented Inhibitor Removal Technology (IRT) to clean impurities from samples and release the DNA from masking by polyphenols. Utilizing a novel bead tube design and further optimized chemistry, the new DNeasy Plant Pro Kit now lyses difficult plant samples, e.g. pine needles, even more efficiently. In comprehensive tests, the DNeasy Plant Pro Kit outperformed all other kits available, including the previous gold standard QIAGEN DNeasy Plant Mini Kit, isolating considerably more high-quality DNA for downstream next generation sequencing (NGS), PCR and other applications. The DNeasy Plant Pro Kit will be an important part of QIAGEN’s trusted offering for plant research from Sample to Insight.
“Since the invention of PCR plant biology has been researched with molecular biology methods, now the focus is on NGS and elucidation of new plant genomes” stated Dominic O’Neil, Director of Microbiome Product Development at QIAGEN. “As such, researchers need a solid basis to isolate DNA suitable for all applications. The DNeasy Plant Pro Kit further advances QIAGEN’s technology and market leading position by taking an already strong product and making it even better and more efficient for laboratories. This new kit can also be automated on the QIAcube® to eliminate manual processing steps and freeing lab staff time. The DNeasy Plant Pro Kit represents an important contribution to QIAGEN’s plant research workflows, which include homogenization, automation, sample prep for plant gDNA or soil microbiome, NGS library prep and bio-informatics solutions.”
Benefits of the DNeasy Plant Pro Kits at a glance
- The new gold standard for DNA isolation from a wide range of plant samples, including the toughest seed types
- Fast and efficient lysis of plant samples
- Significantly higher DNA yields compared to alternative methods
- Recovery of inhibitor-free DNA for direct use in next generation sequencing applications
- Automatable on the QIAcube for fast and standardized sample preparation
QIAGEN’s Leadership in Molecular Biology Research
As an industry pioneer of research solutions for sample preparation, in-depth molecular analyses and data interpretation, QIAGEN is a renowned supplier of tools for plant DNA research worldwide. Additional information can be found at https://www.qiagen.com/us/shop/sample-technologies/dna/genomic-dna/dneasy-powerplant-pro-kit/
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2018, QIAGEN employed approximately 4,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).